Selection of patients for iron-chelating therapy

Emergence of iron aggressive forms in patients with hematological or oncohematological diseases is potentially life-threatening. This can be caused by several situations: multiple allogeneic RBC transfusions, increased intestinal absorption of iron, or damaging effects of chemotherapeutic agents. The objective of the study was to identify candidates for iron-chelating therapy. The data on 727 patients with screening blood tests were analyzed. The highest serum ferritin level was revealed in patients with thalassemia, PMF, or MDS. They received 80, 37, or 35 RBC transfusions, respectively. The lowest serum ferritin levels were found in patients with CLL or hemolytic anemia that received lesser number of RBC transfusions, namely, 18.5 and 16.5, respectively. The correlation between serum ferritin level and the total number of RBC transfusions was revealed: r = 0.462; p = 0.000. We concluded that iron-chelating therapy is primarily indicated to the patients with MDS or PMF in whom the high serum ferritin level is due to excessive post-transfusion iron.

• S.V. Gritsaev Russian Research Institute of Hematology and Transfusiology, FMBA, Saint Petersburg, Russian Federation ; ФГБУ «Российский научно-исследовательский институт гематологии и трансфузиологии Федерального медико-биологического агентства», Санкт-Петербург, Российская Федерация
• B. Davaasambuu Russian Research Institute of Hematology and Transfusiology, FMBA, Saint Petersburg, Russian Federation ; ФГБУ «Российский научно-исследовательский институт гематологии и трансфузиологии Федерального медико-биологического агентства», Санкт-Петербург, Российская Федерация
• N.A. Romanenko Russian Research Institute of Hematology and Transfusiology, FMBA, Saint Petersburg, Russian Federation ; ФГБУ «Российский научно-исследовательский институт гематологии и трансфузиологии Федерального медико-биологического агентства», Санкт-Петербург, Российская Федерация
• K.M. Abdulkadyrov Russian Research Institute of Hematology and Transfusiology, FMBA, Saint Petersburg, Russian Federation ; ФГБУ «Российский научно-исследовательский институт гематологии и трансфузиологии Федерального медико-биологического агентства», Санкт-Петербург, Российская Федерация

1. Cazzola M., Della Porta M.G., Malcovati L. Clinical relevance of anemia and transfusion iron overload in myelodysplastic syndromes. Hematology (Am. Soc. Hematol. Educ. Program) 2008; 166–75. DOI: https://doi.org/10.1182/asheducation-2008.1.166
2. Gattermann N. Pathophysiological and clinical aspects of iron chelation therapy in MDS. Curr. Pharmac. Design 2012; 18: 3222–34. DOI: https://doi.org/10.2174/1381612811209023222
3. Gattermann N., Rachmilewitz E.A. Iron overload in MDS — pathophysiology, diagnosis, and complications. Ann. Hematol. 2011; 90: 1–10. DOI: https://doi.org/10.1007/s00277-010-1091-1
4. Ghoti H., Fibach E., Merkel D. et al. Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in ironoverloaded patients with myelodysplastic syndromes. Haematologica 2010; 95: 1433–4. DOI: https://doi.org/10.3324/haematol.2010.024992
5. Leitch H.A. Controversies surrounding iron chelation therapy for MDS. Blood Rev. 2011; 25: 17–31. DOI: https://doi.org/10.1016/j.blre.2010.09.003
6. Origa R., Galanello R., Ganz T. et al. Liver iron concentrations and urinary hepcidin in b-thalassemia. Haematologica 2007; 92: 583–8. DOI: https://doi.org/10.3324/haematol.10842
7. Park S., Sapena R., Keladi C. et al. Ferritin level at diagnosis is not correlated with poorer survival in non RBC transfusion dependent lower risk de novo MDS. Leuk. Res. 2011; 35: 1530–3. DOI: https://doi.org/10.1016/j.leukres.2011.07.007
8. Knovich M.A., Storey J.A., Coffman L.G., Torti S.V. Ferritin for the clinician. Blood Rev. 2009; 23: 95–104. DOI: https://doi.org/10.1016/j.blre.2008.08.001
9. Armand P., Kim H.T. Rhodes J. et al. Iron overload in patients with acute leukemia or MDS undergoing myeloablative stem cell transplantation. Biol. Blood Marrow Transplant. 2011; 17: 852–60. DOI: https://doi.org/10.1016/j.bbmt.2010.09.006
10. Brittenham G.M., Cohen A.R., McLaren C.E. et al. Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am. J. Hematol. 1993; 42: 81–5. DOI: https://doi.org/10.1002/ajh.2830420116
11. Roghi A., Cappellini M.D., Wood J.C. et al. Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study. Ann. Hematol. 2010; 89: 585–9. DOI: https://doi.org/10.1007/s00277-009-0879-3
12. Taher A., Rassi F.E., Ismaeel H. et al. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica 2008; 93: 1584–5. DOI: https://doi.org/10.3324/haematol.13098
13. Piga A., Longo F., Duca L. et al. High nontransferrin bound iron levels and heart disease in thalassemia major. Am. J. Hematol. 2009; 84: 29–33. DOI: https://doi.org/10.1002/ajh.21317
14. Sahlstedt L., von Bonsdorff L., Ebeling F. et al. Non-transferrin-bound iron in haematological patients during chemotherapy and conditioning for autologous stem cell transplantation. Eur. J. Haematol. 2009; 83: 455–9. DOI: https://doi.org/10.1111/j.1600-0609.2009.01310.x
15. Sahlstedt L., Ebeling F. von Bonsdorff L. et al. Non-transferrin-bound iron during allogeneic stem cell transplantation. Br. J. Haematol. 2001; 113: 836–8. DOI: https://doi.org/10.1046/j.1365-2141.2001.02820.x
16. Andrews N.C. Disorders of iron metabolism. New Engl. J. Med. 1999; 341: 1986–95. DOI: https://doi.org/10.1056/NEJM199912233412607
17. Porter J.B. Practical management of iron overload. Br. J. Haematol. 2001; 115: 239–52. DOI: https://doi.org/10.1046/j.1365-2141.2001.03195.x
18. Dreyfus F. The deleterious effects of iron overload in patients with myelodysplastic syndromes. Blood Rev. 2008; 22(Suppl. 2): S29–34. DOI: https://doi.org/10.1016/S0268-960X(08)70006-7
19. Malcovati L., Porta M.G., Pascutto C. et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision making. J. Clin. Oncol. 2005; 23: 7594–603. DOI: https://doi.org/10.1200/JCO.2005.01.7038
20. Pakbaz Z., Fischer R., Fung E. et al. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients. Pediatr. Blood Cancer 2007; 49: 329–32. DOI: https://doi.org/10.1002/pbc.21275
21. Karam L.B., Disco D., Jackson S.M. et al. Liver biopsy results in patients with sickle cell disease on chronic transfusions: poor correlation with ferritin levels. Pediatr. Blood Cancer 2008; 50: 62–5. DOI: https://doi.org/10.1002/pbc.21215
22. Nielsen P., Gunther U., Durken M. et al. Serum ferritin iron in iron overload and liver damage: correlation to body iron stores and diagnostic relevance. J. Lab. Clin. Med. 2000; 135: 413–8. DOI: https://doi.org/10.1067/mlc.2000.106456
23. Valent P., Krieger O., Stauder R. et al. Iron overload in myelodysplastic syndromes (MDS) — diagnosis, management, and response criteria: a proposal of the Austrian MDS platform. Eur. J. Clin. Invest. 2008; 38: 143–9. DOI: https://doi.org/10.1111/j.1365-2362.2007.01915.x
24. Alessandrino E.P., Della Porta M.G., Bacigalupo A. et al. Prognostic impact of pre-transplantation transfusion history and secondary iron overload in patients with myelodysplastic syndrome undergoing allogeneic stem cell transplantation: a GITMO study. Haematologica 2010; 95: 476–84. DOI: https://doi.org/10.3324/haematol.2009.011429
25. Pullarkat V. Iron overload in patients undergoing hematopoietic stem cell transplantation. Adv. Hematol. 2010; pii: 345756. DOI: https://doi.org/10.1155/2010/345756
26. Грицаев С.В., Абдулкадыров К.М., Шихбабаева Д.И. Миелодиспла- стический синдром (МДС) и перегрузка железом (результаты скрининго- вого обследования 289 больных de novo МДС). Фарматека 2010; 10: 60–7. Gritsayev S.V., Abdulkadyrov K.M., [Shikhbabayeva D.I. Miyelodisplasticheskiy sindrom (MDS) i peregruzka zhelezom (rezultaty skriningovogo obsledovaniya 289 bolnykh de novo MDS) (Myelodisplastic syndrome (MDS) and iron overload (screening study results in 289 patients with de novo MDS)). Farmateka 2010; 10: 60–7.]
27. Pullarkat V., Blanchard S., Tegtmeier B. et al. Iron overload adversely affects outcome of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2008; 42: 799–805. DOI: https://doi.org/10.1038/bmt.2008.262
28. Kushner J.P., Porter J.P., Olivieri N.F. Secondary iron overload. Hematology (Am. Soc. Hematol. Educ. Program) 2001: 47–61. DOI: https://doi.org/10.1182/asheducation-2001.1.47
29. Angelucci E., Barosi G., Camaschella C. et al. Italian Society of Hematology practice guidelines for the management of iron overload in thalassemia major and related disorders. Haematologica 2008; 93: 741–52. DOI: https://doi.org/10.3324/haematol.12413
30. de Swart L., Smith A., Fenaux P. et al. Transfusion-dependency is the most important prognostic factor for survival in 1000 newly diagnosed MDS patients with low- and intermediate-1 risk MDS in the European LeukemiaNet MDS registry. Blood 2011; 118: Abstract 2775. DOI: https://doi.org/10.1182/blood.V118.21.2775.2775
31. Armand P., Sainvil M.-M., Kim H.T. et al. Pre-transplantation iron chelation in patients with MDS or acute leukemia and iron overload undergoing myeloablative allo-SCT. Bone Marrow Transplantat. 2012 May 21. doi: 10.1038/ bmt.2012.94.
32. Cappellini M.D., Porter J., El-Beshlawy A. et al. Tailoring iron chelation by iron intake and serum ferritin: the prospective EPIC study of deferasirox in 1744 patients with transfusion-dependent anemias. Haematologica 2010; 95: 557–66. DOI: https://doi.org/10.3324/haematol.2009.014696
33. Cilloni D., Messa E., Biale L. et al. High rate of erythroid response during iron chelation therapy in a cohort of 105 patients affected by hematologic malignancies with transfusional iron overload: an Italian multicenter retrospective study. Blood 2011; 118: Abstract 611. DOI: https://doi.org/10.1182/blood.V118.21.611.611
34. Gattermann N., Finelli C., Della Porta M. et al. Hematologic responses to deferasirox therapy in transfusion-dependent patients with myelodysplastic syndromes. Haematologica 2012; 97: 1364–71. DOI: https://doi.org/10.3324/haematol.2011.048546
35. Neukirchen J., Fox F., Kundgen A. et al. Improved survival in MDS patients receiving iron chelation therapy — a matched pair analysis of 188 patients from the Dusseldorf MDS registry. Leuk. Res. 2012; 36: 1067–70. DOI: https://doi.org/10.1016/j.leukres.2012.04.006
36. Pullarkat V. Objectives of iron chelation therapy in myelodysplastic syndromes: more than meets the eye? Blood 2009; 114: 5251–5. DOI: https://doi.org/10.1182/blood-2009-07-234062
37. Leitch H.A., Chase J.M., Goodman T.A. et al. Improved survival in red blood cell transfusion dependent patients with primary myelofibrosis (PMF) receiving iron chelation therapy. Hematol. Oncol. 2010; 28: 40–8. DOI: https://doi.org/10.1002/hon.902
38. Armand P., Kim H.T., Cutler S.C. et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood 2007; 109: 4586–8. DOI: https://doi.org/10.1182/blood-2006-10-054924
39. Kanda J., Kawabata H., Chao N.J. Iron overload and allogeneic hematopoietic stem-cell transplantation. Expert Rev. Hematol. 2011; 4: 71–80. DOI: https://doi.org/10.1586/ehm.10.81
40. Lim Z.Y., Fiaccadori V., Gandhi S. et al. Impact of pre-transplant serum ferritin on outcomes of patients with myelodysplastic syndromes or secondary acute myeloid leukemia receiving reduced intensity conditioning allogeneic haematopoietic stem cell transplantation. Leuk. Res. 2010; 34: 723–7. DOI: https://doi.org/10.1016/j.leukres.2009.10.028
41. Maradei S.C., Maiolino A., de Azevedo A.M. et al. Serum ferritin as risk factor for sinusoidal obstruction syndrome of the liver in patients undergoing hematopoietic stem cell transplantation. Blood 2009; 114: 1270–5. DOI: https://doi.org/10.1182/blood-2009-03-212282
42. Platzbecker U., Bornhauser M., Germing U. et al. Red blood cell transfusion-dependence and outcome after allogeneic peripheral blood stem cell transplantation in patients with de novo myelodysplastic syndromes (MDS). Biol. Blood Marrow Transplant. 2008; 14: 1217–25. DOI: https://doi.org/10.1016/j.bbmt.2008.08.006
43. Tanaka V., Tachibana N., Numata A. et al. A prognostic score with pretransplant serum ferritin and disease status predicts outcome following reduced-intensity SCT. Bone Marrow Transplant. 2012; 47: 596–7. DOI: https://doi.org/10.1038/bmt.2011.122
44. Lee J.W., Kang H.J., Kim E.K. et al. Effect of iron overload and ironchelating therapy on allogeneic hematopoietic SCT in children. Bone Marrow Transplant. 2009; 44: 793–7. DOI: https://doi.org/10.1038/bmt.2009.88
45. Fritsch A., Langebrake C., Nielsen P. et al. Deferasirox (Exjade®) given during conditioning regimen (FLAMSA/Busulfan/ATG) reduces the appearance of labile plasma iron in patients undergoing allogeneic stem cell transplantation. Blood 2011; 118: Abstract 3023. DOI: https://doi.org/10.1182/blood.V118.21.3023.3023
46. Armand P., Sainvil M.-M., Kim H.T. et al. Does iron overload really matter in stem cell transplantation? Am. J. Hematol. 2012; 87: 569–72. DOI: https://doi.org/10.1002/ajh.23188
47. Pardanani A., Tefferi A. Prognostic relevance of anemia and transfusion dependency in myelodysplastic syndromes and primary myelofibrosis. Haematologica 2011; 96: 8–10. DOI: https://doi.org/10.3324/haematol.2010.035519
48. Ali S., Pimentel J.D., Munoz J. et al. Iron overload in allogeneic hematopoietic stem cell transplant recipients. Arch. Pathol. Lab. Med. 2012; 136: 532–8. DOI: https://doi.org/10.5858/arpa.2011-0190-OA